[Clinical evaluation of imipenem/cilastatin sodium in children].

Abstract

Nine pediatric patients with moderate or severe bacterial infections (3 septicemia or bacteremia, 2 pyelitis, 2 tonsillitis, 1 pneumonia and 1 pyothorax) in hospital were treated with MK-0787/MK-0791. The drug was administered intravenously by 30 or 60 minutes drip infusion in 3 or 4 divided doses totalling 24 mg/24 mg-70.2 mg/70.2 mg per kg/day. Clinical effectiveness were excellent in 4 cases, good in 2 cases, poor in 2 cases and not evaluated in 1 case. The overall efficacy rate was 75%. A slight decrease of WBC was observed in 1 case. It was concluded that MK-0787/MK-0791 was a useful antibiotic for the treatment of infections in pediatric practices. Pharmacokinetics of intravenously administered MK-0787/MK-0791 was studied in 2 other cases. The MK-0787/MK-0791 was administered intravenously by 30 or 60 minutes drip infusion to 2 cases at a dose of 10 mg/10 mg/kg. The mean half-life (T1/2) of MK-0787 was 1.03 hours and MK-0791, 0.69 hour. The mean urinary recovery rate of MK-0787 within 6.5-7 hours after administration was 62.5% and MK-0791, 76.7%.

• Authors: I Nagamatsu, Y Tateno, Y Wagatsuma, A Takase, S Horiguchi, Y Kusunoki
• Journal: The Japanese journal of antibiotics (Jpn J Antibiot) Vol. 39 Issue 7 Pg. 1693-700 (Jul 1986) ISSN: 0368-2781 [Print] Japan
• PMID: 3464773 (Publication Type: English Abstract, Journal Article)

Chemical References

• Cyclopropanes
• Drug Combinations
• Thienamycins
• Cilastatin
• Imipenem

Topics

• Adolescent
• Bacterial Infections (drug therapy)
• Child
• Child, Preschool
• Cilastatin
• Cyclopropanes (administration & dosage)
• Drug Combinations
• Empyema (drug therapy)
• Female
• Humans
• Imipenem
• Infant
• Infusions, Intravenous
• Kinetics
• Male
• Pneumonia, Staphylococcal (drug therapy)
• Pyelitis (drug therapy)
• Sepsis (drug therapy)
• Thienamycins (administration & dosage)
• Tonsillitis (drug therapy)